Pharmaceuticals Italy

Italy Newborn Genome Sequencing Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Italy Newborn Genome Sequencing Market Industry Trends and Forecast to 2034: Segmented by (Program, Condition, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Italy · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $9.8 Mn Placeholder estimate
Estimate 2025 $11.7 Mn 2.7% of the global market
Projected 2034 $58.7 Mn 400.7% Adds $47.0 Mn over 9 forecast years
CAGR 2025–2034 19.6% Faster than 88% of 180 Pharmaceuticals markets here
Key players 5 Companies profiled
  • Italy is 2.72% of the global market.
  • In Europe, the largest is Germany at $13.7 Mn.
  • Fastest growing: Russia at 20.2% a year.
  • Italy ranks 3rd of 6 by size in Europe.

Market size projection

Italy

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$47.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Newborn Genome Sequencing Market market size by year, Italy
YearMarket sizeChange that yearSince 2025
2024 (estimate) $9.8 Mn — —
2025 (base) $11.7 Mn +$1.9 Mn —
2026 (forecast) $14.0 Mn +$2.3 Mn +19.6%
2027 (forecast) $16.8 Mn +$2.7 Mn +43%
2028 (forecast) $20.1 Mn +$3.3 Mn +71.1%
2029 (forecast) $24.0 Mn +$3.9 Mn +104.6%
2030 (forecast) $28.7 Mn +$4.7 Mn +144.7%
2031 (forecast) $34.3 Mn +$5.6 Mn +192.7%
2032 (forecast) $41.1 Mn +$6.7 Mn +250%
2033 (forecast) $49.1 Mn +$8.0 Mn +318.6%
2034 (forecast) $58.7 Mn +$9.6 Mn +400.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Italy Newborn Genome Sequencing Market Analysis at a glance
Market size, 2025$11.7 Mn placeholder estimate
Forecast, 2034$58.7 Mn placeholder estimate
Growth (CAGR), 2025–203419.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProgram, condition and end user (see all)
Key playersIllumina, Inc., GeneDx, Natera, Genomics England, Fulgent Genetics (see all)
Regulator in ItalyAIFASource: Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Italy Newborn Genome Sequencing Market Analysis Executive Summary

Newborn genome sequencing reads a baby's DNA to find treatable genetic conditions early, beyond standard newborn screening.

Key segments of the newborn Genome Sequencing market include program (Research Programs, National Screening Pilots and Private Testing) and condition (Metabolic, Immune and Neurological).

Bar chart: Italy Newborn Genome Sequencing market size, 2024–2034, placeholder estimates. $9.8 Mn in 2024, $11.7 Mn in 2025 and $58.7 Mn in 2034, 19.6% CAGR.
Italy Newborn Genome Sequencing market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Italy Newborn Genome Sequencing Market Dynamics

Market Growth Drivers

The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the newborn Genome Sequencing market.

Opportunity

Routine use of genomics in screening, pharmacy and primary care gives the newborn Genome Sequencing market large room to grow.

Market Restraints

Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the newborn Genome Sequencing market.

Competitive Landscape for Newborn Genome Sequencing Market in Italy

The newborn Genome Sequencing market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Newborn Genome Sequencing Market in Italy

Newborn Genome Sequencing in Italy: rules and payment

Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AIFA, the Italian Medicines Agency, which also negotiates prices and reimbursement.⁠[1] The National Health Service (SSN), run by the regions, gives universal cover, and AIFA decides which medicines it pays for.⁠[2]

[1] Italian Medicines Agency (AIFA). Checked 14 Nov 2026.

[2] Italian Ministry of Health. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for newborn Genome Sequencing. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Italy.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Newborn Genome Sequencing right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Newborn Genome Sequencing in context

Italy compared

  • Health spending per person: 3,398 US$ per person (2024). World: 1,317 US$ per person (2023). 4th highest of the 6 countries we cover in Europe.[1]
  • Doctors: 4.19 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 4th highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 25.1% of people (2025). World: 10.4% of people (2025). Highest of the 6 countries we cover in Europe.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 15 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Newborn Genome Sequencing market in Italy?
Placeholder estimate: about $11.7 Mn in 2025, rising to about $58.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Newborn Genome Sequencing market in Italy growing?
Placeholder estimate: about 19.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Newborn Genome Sequencing market report cover?
The report splits the market by program (Research Programs, National Screening Pilots, Private Testing), condition (Metabolic, Immune, Neurological, Cardiac) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Newborn Genome Sequencing market?
Key players include Illumina, Inc., GeneDx, Natera, Genomics England and Fulgent Genetics.
What is driving the Newborn Genome Sequencing market?
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the newborn Genome Sequencing market.
Who regulates Newborn Genome Sequencing in Italy?
Medicines are authorised either for the whole EU by the European Commission, after review by the European Medicines Agency (EMA), or nationally by AIFA, the Italian Medicines Agency, which also negotiates prices and reimbursement. Source: Italian Medicines Agency (AIFA). Checked 14 Nov 2026.
How is healthcare paid for in Italy?
The National Health Service (SSN), run by the regions, gives universal cover, and AIFA decides which medicines it pays for. Source: Italian Ministry of Health. Checked 14 Nov 2026.
How much research is published on Newborn Genome Sequencing?
PubMed lists 53 papers on Newborn Genome Sequencing added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Italy

See all

Related on genomics and neonatal

See the topic